Pub Date : 2026-02-12DOI: 10.1016/j.jaad.2026.02.025
Frank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, Tracy I George, Cristina Bulai Livideanu, Ivan Alvarez-Twose, Jens Panse, Stéphane Barete, Andreas Reiter, Ingunn Dybedal, Cem Akin, Paul Van Daele, Deepti H Radia, Sonia Cerquozzi, Celalettin Ustun, Vito Sabato, Jason Gotlib, Mark Rafferty, Daniel J DeAngelo, Philippe Schafhausen, Johanna Ungerstedt, Princess U Ogbogu, Scott Florell, David A Wada, Anton Rets, Hui-Min Lin, Ilda Bidollari, Janet Hong, Daniel Shaheen, Benjamin Lampson, Karin Hartmann
Background: Indolent systemic mastocytosis (ISM), a clonal mast cell disease driven by the KIT D816V mutation, can often cause debilitating dermatologic symptoms.
Objective: Assess improvement of ISM-related skin manifestations after treatment with avapritinib, a highly selective KIT D816V inhibitor, vs placebo in Part 2 of the PIONEER study (NCT03731260).
Methods: Patients with moderate-to-severe ISM received avapritinib 25 mg once daily (n=141) or placebo (n=71). Endpoints included skin lesion area and pigmentation at week 24, skin mast cell burden, and change in symptoms.
Results: Mean percent reduction in lesional surface area was -36.6% with avapritinib vs -1.8% with placebo in the most affected area; 86% vs 0% had improved skin lesion color. Mean percent change in skin mast cell burden decreased with avapritinib (-22.1%) vs placebo (10.1%). Avapritinib vs placebo significantly improved skin symptom domain score (mean change -7.2 vs -2.8; p<.0001), including the individual skin symptoms itching, flushing, and spots. Avapritinib was well tolerated.
Limitations: Photography was optional, so analysis population for lesion area and color were smaller (n=111) than the overall study population (n=212).
Conclusion: Avapritinib treatment improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion color, and reduced skin mast cell burden in patients with ISM.
背景：惰性全身性肥大细胞增多症（ISM）是一种由KIT D816V突变驱动的克隆性肥大细胞疾病，通常会导致皮肤症状的衰弱。目的：在PIONEER研究（NCT03731260）的第二部分中，评估阿伐替尼（一种高选择性KIT D816V抑制剂）与安慰剂治疗后ism相关皮肤症状的改善。方法：中重度ISM患者给予阿伐替尼25mg，每日1次（n=141）或安慰剂（n=71）。终点包括第24周皮肤病变面积和色素沉着、皮肤肥大细胞负荷和症状变化。结果：在最受影响的区域，阿伐替尼组的平均病灶表面积减少率为-36.6%，安慰剂组为-1.8%；86%对0%的患者皮肤病变颜色有所改善。阿伐替尼组皮肤肥大细胞负荷的平均变化百分比（-22.1%）比安慰剂组（10.1%）降低。与安慰剂相比，Avapritinib显著改善了皮肤症状域评分（平均变化-7.2 vs -2.8）；局限性：摄影是可选的，因此病变面积和颜色的分析人群（n=111）小于总体研究人群（n=212）。结论：阿伐替尼治疗可改善ISM患者的皮肤症状，缩小皮肤病变大小，使皮肤病变颜色正常化，减轻皮肤肥大细胞负担。
{"title":"Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.","authors":"Frank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, Tracy I George, Cristina Bulai Livideanu, Ivan Alvarez-Twose, Jens Panse, Stéphane Barete, Andreas Reiter, Ingunn Dybedal, Cem Akin, Paul Van Daele, Deepti H Radia, Sonia Cerquozzi, Celalettin Ustun, Vito Sabato, Jason Gotlib, Mark Rafferty, Daniel J DeAngelo, Philippe Schafhausen, Johanna Ungerstedt, Princess U Ogbogu, Scott Florell, David A Wada, Anton Rets, Hui-Min Lin, Ilda Bidollari, Janet Hong, Daniel Shaheen, Benjamin Lampson, Karin Hartmann","doi":"10.1016/j.jaad.2026.02.025","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.025","url":null,"abstract":"<p><strong>Background: </strong>Indolent systemic mastocytosis (ISM), a clonal mast cell disease driven by the KIT D816V mutation, can often cause debilitating dermatologic symptoms.</p><p><strong>Objective: </strong>Assess improvement of ISM-related skin manifestations after treatment with avapritinib, a highly selective KIT D816V inhibitor, vs placebo in Part 2 of the PIONEER study (NCT03731260).</p><p><strong>Methods: </strong>Patients with moderate-to-severe ISM received avapritinib 25 mg once daily (n=141) or placebo (n=71). Endpoints included skin lesion area and pigmentation at week 24, skin mast cell burden, and change in symptoms.</p><p><strong>Results: </strong>Mean percent reduction in lesional surface area was -36.6% with avapritinib vs -1.8% with placebo in the most affected area; 86% vs 0% had improved skin lesion color. Mean percent change in skin mast cell burden decreased with avapritinib (-22.1%) vs placebo (10.1%). Avapritinib vs placebo significantly improved skin symptom domain score (mean change -7.2 vs -2.8; p<.0001), including the individual skin symptoms itching, flushing, and spots. Avapritinib was well tolerated.</p><p><strong>Limitations: </strong>Photography was optional, so analysis population for lesion area and color were smaller (n=111) than the overall study population (n=212).</p><p><strong>Conclusion: </strong>Avapritinib treatment improved dermatologic symptoms, decreased skin lesion size, normalized skin lesion color, and reduced skin mast cell burden in patients with ISM.</p>","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1016/j.jaad.2026.02.030
Racha Cherradi, Jennifer Ezuruike, Safiya Haque, Iman Bouchelkia, Harrison Nguyen
{"title":"Syphilis and Risk of Cutaneous Squamous Cell Carcinoma.","authors":"Racha Cherradi, Jennifer Ezuruike, Safiya Haque, Iman Bouchelkia, Harrison Nguyen","doi":"10.1016/j.jaad.2026.02.030","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.030","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1016/j.jaad.2026.02.026
Ngoc-Trang Adrienne H Nguyen, Harrison P Nguyen
{"title":"Skin Lightening at the Intersection of Misinformation, Regulatory Gaps, and Global Inequity.","authors":"Ngoc-Trang Adrienne H Nguyen, Harrison P Nguyen","doi":"10.1016/j.jaad.2026.02.026","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.026","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":" ","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146197698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to Chen et al., \"Dupilumab, Atopic Dermatitis, and Linear Growth: Navigating Beyond Association to Mechanism and Intervention.\"","authors":"Tai-Li Chen, Sheng-Hsiang Ma, Wei-Fan Ou, Chih-Chiang Chen, Chen-Yi Wu","doi":"10.1016/j.jaad.2026.02.020","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.020","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"32 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146152653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.jaad.2026.01.087
Ke Yang, Xing Wen, Xu Chen
{"title":"Dupilumab, Atopic Dermatitis, and Linear Growth: Navigating Beyond Association to Mechanism and Intervention","authors":"Ke Yang, Xing Wen, Xu Chen","doi":"10.1016/j.jaad.2026.01.087","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.01.087","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"10 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.jaad.2026.02.019
Daniel Y. Kim, Timothy M. Dang, Jennifer T. Huang, Sasha Stephen, Thomas S. Kupper, Cecilia Larocca, Nicole R. LeBoeuf
{"title":"Increasing Incidence of Cutaneous T-Cell Lymphoma Among Children and Young Adults in the United States, 1997–2019: A National Population-Based Study Using the National Childhood Cancer Registry","authors":"Daniel Y. Kim, Timothy M. Dang, Jennifer T. Huang, Sasha Stephen, Thomas S. Kupper, Cecilia Larocca, Nicole R. LeBoeuf","doi":"10.1016/j.jaad.2026.02.019","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.019","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"186 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.jaad.2026.02.022
Jourdan A. Hydol-Smith, Kateri Schoettinger, Rachel M. Kirven, Sabrina Shearer, Abraham M. Korman, Misha Rosenbach, Daniela Kroshinsky, Benjamin H. Kaffenberger
{"title":"Outpatient care activities of inpatient dermatologists between 2013-2019 reveal unique practice patterns","authors":"Jourdan A. Hydol-Smith, Kateri Schoettinger, Rachel M. Kirven, Sabrina Shearer, Abraham M. Korman, Misha Rosenbach, Daniela Kroshinsky, Benjamin H. Kaffenberger","doi":"10.1016/j.jaad.2026.02.022","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.022","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"10 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-11DOI: 10.1016/j.jaad.2026.02.021
Savannah Alvarado, Van Anh Tran, Victoria P. Werth, Emily Baumrin
{"title":"Chronic GVHD has similar or worse impact on skin-specific quality of life than autoimmune connective tissue diseases: a cross-sectional study","authors":"Savannah Alvarado, Van Anh Tran, Victoria P. Werth, Emily Baumrin","doi":"10.1016/j.jaad.2026.02.021","DOIUrl":"https://doi.org/10.1016/j.jaad.2026.02.021","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"71 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1016/j.jaad.2025.11.109
Qianting Lu, Yafei Wang, Xin Zhao
{"title":"Clinical Perspective on Staging, Treatment Timing, and Survival Interpretation in Vulvar Squamous Cell Carcinoma","authors":"Qianting Lu, Yafei Wang, Xin Zhao","doi":"10.1016/j.jaad.2025.11.109","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.11.109","url":null,"abstract":"","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"18 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146152685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10DOI: 10.1016/j.jaad.2025.09.101
Seemal R. Desai MD, Allison T. Vidimos MD RPh, Edmund J. Elder PhD RPh, Gigi Davidson BSPharm, the Compounding Work Group, Murad Alam MD MBA MSCI, Daniel D. Bennett MD, Brett M. Coldiron MD, George J. Hruza MBA MD, Leon H. Kircik MD, Kelley Pagliai Redbord MD, Sabra Sullivan MD PhD, Chad Appel JD, Lisa Albany JD
Buffered lidocaine is widely used in dermatologic and other in-office procedures to reduce injection pain and expedite onset of anesthesia. Current United States Pharmacopeia <797> standards limit immediate-use compounded sterile preparations to administration within 4 hours, creating significant barriers for dermatology practices where buffered lidocaine is routinely prepared in advance of patient visits. In collaboration with the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and United States Pharmacopeia, the American Academy of Dermatology Association, American College of Mohs Surgery, American Society for Dermatologic Surgery, and American Society for Mohs Surgery initiated development of a United States Pharmacopeia monograph to establish evidence-based beyond-use dates for buffered lidocaine.
{"title":"In-office compounding of buffered lidocaine and epinephrine – A stability and safety review","authors":"Seemal R. Desai MD, Allison T. Vidimos MD RPh, Edmund J. Elder PhD RPh, Gigi Davidson BSPharm, the Compounding Work Group, Murad Alam MD MBA MSCI, Daniel D. Bennett MD, Brett M. Coldiron MD, George J. Hruza MBA MD, Leon H. Kircik MD, Kelley Pagliai Redbord MD, Sabra Sullivan MD PhD, Chad Appel JD, Lisa Albany JD","doi":"10.1016/j.jaad.2025.09.101","DOIUrl":"https://doi.org/10.1016/j.jaad.2025.09.101","url":null,"abstract":"Buffered lidocaine is widely used in dermatologic and other in-office procedures to reduce injection pain and expedite onset of anesthesia. Current United States Pharmacopeia <797> standards limit immediate-use compounded sterile preparations to administration within 4 hours, creating significant barriers for dermatology practices where buffered lidocaine is routinely prepared in advance of patient visits. In collaboration with the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, and United States Pharmacopeia, the American Academy of Dermatology Association, American College of Mohs Surgery, American Society for Dermatologic Surgery, and American Society for Mohs Surgery initiated development of a United States Pharmacopeia monograph to establish evidence-based beyond-use dates for buffered lidocaine.","PeriodicalId":17198,"journal":{"name":"Journal of the American Academy of Dermatology","volume":"16 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146146729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号